CENTRAL TRUST Co Decreases Stock Position in Solventum Co. (NYSE:SOLV)

CENTRAL TRUST Co cut its stake in Solventum Co. (NYSE:SOLV) by 5.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,887 shares of the company’s stock after selling 402 shares during the period. CENTRAL TRUST Co’s holdings in Solventum were worth $455,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. Spire Wealth Management acquired a new stake in Solventum in the fourth quarter valued at $37,000. Tokio Marine Asset Management Co. Ltd. raised its stake in Solventum by 5.3% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,227 shares of the company’s stock valued at $345,000 after buying an additional 261 shares in the last quarter. Crews Bank & Trust acquired a new stake in Solventum in the fourth quarter valued at $32,000. Synergy Asset Management LLC acquired a new stake in Solventum in the fourth quarter valued at $35,000. Finally, Forsta AP Fonden acquired a new stake in Solventum in the fourth quarter valued at $1,876,000.

Solventum Stock Up 1.4 %

SOLV opened at $74.62 on Wednesday. The business has a 50 day moving average price of $70.21 and a two-hundred day moving average price of $67.57. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.05 billion. On average, equities research analysts predict that Solventum Co. will post 6.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SOLV. Piper Sandler raised their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Mizuho started coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Finally, Stifel Nicolaus started coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.